{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:33:33Z","timestamp":1793043213550,"version":"4.5.0"},"reference-count":178,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/19420862.2022.2153410","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:06:24Z","timestamp":1670317584000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":284,"title":["Antibodies to watch in 2023"],"prefix":"10.1080","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2195","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"first","affiliation":[{"name":"Institut de Recherches Internationales Servier","place":["Suresnes, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-5957","authenticated-orcid":false,"given":"Silvia","family":"Crescioli","sequence":"additional","affiliation":[{"name":"King\u2019s College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-9268","authenticated-orcid":false,"given":"Alicia","family":"Chenoweth","sequence":"additional","affiliation":[{"name":"King\u2019s College London","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6181-2438","authenticated-orcid":false,"given":"Jyothsna","family":"Visweswaraiah","sequence":"additional","affiliation":[{"name":"Seismic Therapeutic","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"The Antibody Society Inc","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.2014296"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1860476"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1703531"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1415671"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1269580"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1125583"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2015.988944"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27333"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22976"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.1.18719"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.3.1.13895"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.1.10677"},{"key":"e_1_3_5_15_1","unstructured":"U.S. Food and Drug Administration. Emergency Use Authorization. [accessed 2022 Nov 19]. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1101\/2022.09.05.506628"},{"key":"e_1_3_5_17_1","unstructured":"InflaRx NV InflaRx submits request for Emergency Use Authorization to US FDA for vilobelimab for treatment of critically ill COVID-19 patients. September 29 2022 press release [accessed 2022 Nov 12]. https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/09-2022-InflaRx-Submits-Request-for-Emergency-Use-Authorization-to-US-FDA-for-Vilobelimab-for-Treatment-of-Critically-Ill-COVID-19-Patients-.html."},{"key":"e_1_3_5_18_1","unstructured":"The Antibody Society Inc. Antibody therapeutics approved or in regulatory review in the EU or US. [accessed 2022 Nov 18]. https:\/\/www.antibodysociety.org\/resources\/approved-antibodies\/."},{"key":"e_1_3_5_19_1","unstructured":"Immunocore Holdings pl. Immunocore announces FDA approval of KIMMTRAK\u00ae (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma. January 26 2022 press release [accessed 2022 August 25]. https:\/\/ir.immunocore.com\/news-releases\/news-release-details\/immunocore-announces-fda-approval-kimmtrakr-tebentafusp-tebn."},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"e_1_3_5_21_1","unstructured":"Genentech. FDA approves Genentech\u2019s Vabysmo the first bispecific antibody for the eye to treat two leading causes of vision loss. January 28 2022 press release [accessed 2022 Aug 23]. https:\/\/www.gene.com\/media\/press-releases\/14943\/2022-01-28\/fda-approves-genentechs-vabysmo-the-firs."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_5_24_1","unstructured":"Genentech. New two-year data confirm Genentech\u2019s Vabysmo improves vision with fewer treatments for people with wet-age-related macular degeneration. July 14 2022 press release [accessed 2022 Aug 23]. https:\/\/www.gene.com\/media\/press-releases\/14960\/2022-07-14\/new-two-year-data-confirm-genentechs-vab."},{"key":"e_1_3_5_25_1","unstructured":"Sanofi. FDA approves Enjaymo\u2122 (sutimlimab-jome) first treatment for use in patients with cold agglutinin disease. February 4 2022 press release [accessed 2022 Aug 23]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-02-04-22-00-00-2379517."},{"key":"e_1_3_5_26_1","unstructured":"Sanofi. European commission approves enjaymo\u00ae (sutimlimab) for treatment of hemolytic anemia in adult patients with cold agglutinin disease. Nov 17 2022 press release [accessed 2022 Nov 18]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-11-17-17-50-00-2558583."},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955"},{"key":"e_1_3_5_28_1","unstructured":"Bristol Myers Squibb US Food and Drug Administration approves first LAG-3-blocking antibody combination Opdualag\u2122 (nivolumab and relatlimab-rmbw) as treatment for patients with unresectable or metastatic melanoma. March 18 2022 press release [accessed 2022 Aug 23]. https:\/\/news.bms.com\/news\/corporate-financial\/2022\/U.S.-Food-and-Drug-Administration-Approves-First-LAG-3-Blocking-Antibody-Combination-Opdualag-nivolumab-and-relatlimab-rmbw-as-Treatment-for-Patients-with-Unresectable-or-Metastatic-Melanoma\/default.aspx."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_5_30_1","unstructured":"AstraZeneca. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. December 8 2021 press release [accessed 2022 Aug 29]. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2021\/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html."},{"key":"e_1_3_5_31_1","unstructured":"U.S. Food and Drug Administration. FDA authorizes revisions to Evusheld dosing. June 29 2022 [accessed 2022 Aug 30]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-authorizes-revisions-evusheld-dosing."},{"key":"e_1_3_5_32_1","unstructured":"AstraZeneca. AstraZeneca\u2019s antibody combination Evusheld (tixagevimab co-packaged with cilgavimab) authorised for use in Great Britain for pre-exposure prophylaxis (prevention) of COVID-19. March 17 2022 [accessed 2022 Aug 30] https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html."},{"key":"e_1_3_5_33_1","unstructured":"AstraZeneca. Evusheld long-acting antibody combination recommended for approval in the EU for the pre-exposure prophylaxis (prevention) of COVID-19. March 24 2022 [2022 Aug 30] https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2022\/evusheld-long-acting-antibody-combination-recommended-for-approval-in-the-eu-for-the-pre-exposure-prophylaxis-prevention-of-covid-19.html."},{"key":"e_1_3_5_34_1","unstructured":"AstraZeneca. Evusheld long-acting antibody combination approved for prevention and treatment of COVID-19 in Japan. August 30 2022 press release [accessed 2022 Aug 30]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/evusheld-approved-for-covid-19-in-japan.html#!."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00180-1"},{"key":"e_1_3_5_36_1","unstructured":"Roche. European Commission approves Roche\u2019s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma. June 8 2022 press release [accessed 2022 Aug 30]. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-06-08."},{"key":"e_1_3_5_37_1","unstructured":"Genentech. FDA grants priority review to Genentech\u2019s mosunetuzumab for people with relapsed or refractory follicular lymphoma. July 5 2022 press release [accessed 2022 Aug 30]. https:\/\/www.gene.com\/media\/press-releases\/14958\/2022-07-05\/fda-grants-priority-review-to-genentechs."},{"key":"e_1_3_5_38_1","unstructured":"The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen marks first approval worldwide for TECVAYLI\u00ae (teclistamab) with EC authorisation of first-in-class bispecific antibody for the treatment of patients with multiple myeloma. August 24 2022 press release [accessed 2022 Aug 30]. https:\/\/www.jnj.com\/janssen-marks-first-approval-worldwide-for-tecvayli-teclistamab-with-ec-authorisation-of-first-in-class-bispecific-antibody-for-the-treatment-of-patients-with-multiple-myeloma."},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_40_1","unstructured":"Boehringer Ingelheim. U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults. September 2 2022 press release [accessed 2022 Sep 2]. https:\/\/www.boehringer-ingelheim.com\/human-health\/skin-diseases\/fda-approves-first-gpp-flare-treatment."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"e_1_3_5_42_1","unstructured":"AstraZeneca. Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer. October 24 2022 press release [accessed 2022 Nov 19]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinzi-and-imjudo-approved-in-advanced-liver-cancer.html."},{"key":"e_1_3_5_43_1","unstructured":"AstraZeneca. Imfinzi and Imjudo with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer. November 11 2022 press release [accessed 2022 Nov 19]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/imfinzi-and-imjudo-approved-in-us-for-lung-cancer.html."},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.379"},{"key":"e_1_3_5_45_1","unstructured":"AstraZeneca. Imfinzi and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer nearly doubling the number of patients alive after three years vs. chemotherapy. September 11 2022 press release [accessed 2022 Sep 25]. https:\/\/www.astrazeneca.com\/content\/astraz\/media-centre\/press-releases\/2022\/imfinzi-and-tremelimumab-with-chemotherapy-demonstrated-sustained-survival-benefit-in-metastatic-non-small-cell-lung-cancer.html."},{"key":"e_1_3_5_46_1","unstructured":"Sanofi. European Commission grants first approval worldwide of Beyfortus\u00ae (nirsevimab) for prevention of RSV disease in infants. November 4 2022 press release [accessed 2022 Nov 19]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-11-04-07-00-00-2548492."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2112186"},{"key":"e_1_3_5_49_1","unstructured":"ImmunoGen Inc. ImmunoGen announces FDA accelerated approval of ELAHERE\u2122 (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer. November 14 2022 press release [accessed 2022 Nov 19]. https:\/\/investor.immunogen.com\/news-releases\/news-release-details\/immunogen-announces-fda-accelerated-approval-elaheretm."},{"key":"e_1_3_5_50_1","unstructured":"ImmunoGen Inc. ImmunoGen presents additional efficacy and safety analyses evaluating mirvetuximab soravtansine in ovarian cancer at ASCO. May 26 2022 press release [accessed 2022 Sept 19]. https:\/\/investor.immunogen.com\/news-releases\/news-release-details\/immunogen-presents-additional-efficacy-and-safety-analyses."},{"key":"e_1_3_5_51_1","unstructured":"ImmunoGen Inc. ImmunoGen presents additional analyses evaluating mirvetuximab soravtansine in ovarian cancer at ESMO. September 11 2022 press release [accessed 2022 Sept 19]. https:\/\/investor.immunogen.com\/news-releases\/news-release-details\/immunogen-presents-additional-analyses-evaluating-mirvetuximab."},{"key":"e_1_3_5_52_1","unstructured":"Provention Bio Inc. TZIELD\u2122 (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D. November 17 2022 press release [accessed 2022 Nov 19]. https:\/\/investors.proventionbio.com\/2022-11-17-TZIELD-TM-teplizumab-mzwv-approved-by-FDA-as-the-first-and-only-treatment-indicated-to-delay-the-onset-of-Stage-3-type-1-diabetes-T1D-in-adult-and-pediatric-patients-aged-8-years-and-older-with-Stage-2-T1D."},{"key":"e_1_3_5_53_1","unstructured":"U.S. Food and Drug Administration. FDA briefing document Endocrinologic and Metabolic Drugs Advisory Committee Meeting May 27 2021: Teplizumab BLA761183. [accessed 2022 Nov 19]. https:\/\/www.fda.gov\/media\/149388\/download."},{"key":"e_1_3_5_54_1","unstructured":"Molecular Targeting Technologies Inc. Molecular Targeting Technologies Inc. Thomas Jefferson University and North China Pharmaceutical Co. Ltd announced the Chinese approval for a rabies drug. January 26 2022 press release [accessed 2022 Sept 19]. https:\/\/www.businesswire.com\/news\/home\/20220126005104\/en\/Molecular-Targeting-Technologies-Inc.-Thomas-Jefferson-University-and-North-China-Pharmaceutical-Co.-Ltd-Announced-the-Chinese-Approval-for-a-Rabies-Drug."},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2022.102267"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081218"},{"key":"e_1_3_5_57_1","unstructured":"Shanghai Henlius Biotech Inc. Henlius receives NMPA approval for its first innovative monoclonal antibody HANSIZHUANG. March 25 2022 press release [accessed 2022 Sept 19]. https:\/\/www.henlius.com\/en\/NewsDetails-3512-26.html."},{"key":"e_1_3_5_58_1","unstructured":"Shanghai Henlius Biotech Inc. Henlius\u2019 novel anti-PD-1 mAb HANSIZHUANG (Serplulimab) receives NMPA approval for the treatment of sqNSCLC. November 1 2022 press release [accessed 2022 Nov 10]. https:\/\/www.henlius.com\/en\/NewsDetails-3837-26.html."},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464"},{"key":"e_1_3_5_60_1","unstructured":"Akeso Inc. Akeso\u2019s cadonilimab (PD-1\/CTLA-4) the first dual immune checkpoint inhibitor to treat cancer approved for marketing in China. June 29 2022 press release [accessed 2022 Sept 19]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/20220629\/."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1724751"},{"key":"e_1_3_5_62_1","unstructured":"Biopharma LEPU. Anti-PD-1 monoclonal antibody Puyouheng (pucotenlimab injection) developed by LEPU BIOPHARMA was approved for marketing by the national medical products administration. July 22 2022 press release [accessed 2022 Sept 19]. https:\/\/en.lepubiopharma.com\/new\/187.html."},{"key":"e_1_3_5_63_1","unstructured":"SinoCellTech Ltd. China Cell\u2019s commercialization process adds new recruits: anpingxi\u00ae - Repertuzumab approved for marketing. August 30 2022 press release [translated from Chinese accessed 2022 Sept 19]. http:\/\/www.sinocelltech.com\/Detail\/desc\/pid\/23\/sid\/363.html."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3054"},{"key":"e_1_3_5_65_1","unstructured":"Maruho Co. Ltd. Maruho acquires manufacturing and marketing approval in Japan for \u201cMitchga subcutaneous injection 60mg syringes\u201d a new treatment targeting itch associated with atopic dermatitis. March 28 2022 press release [accessed 2022 Sept 19]. https:\/\/www.maruho.co.jp\/english\/information\/20220328.html."},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20873"},{"key":"e_1_3_5_67_1","unstructured":"Galderma. Galderma announces positive data from phase III trial demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis. June 22 2022 press release [accessed 2022 Sept 19]. https:\/\/www.galderma.com\/news\/galderma-announces-positive-data-phase-iii-trial-demonstrating-efficacy-and-safety-nemolizumab."},{"key":"e_1_3_5_68_1","unstructured":"Taisho Pharmaceutical Co. Ltd. Notification of approval to manufacture and market Nanozora\u00ae 30mg syringes for S.C. injection a therapy for rheumatoid arthritis in Japan: Japan\u2019s first NANOBODY\u00ae therapeutic. September 26 2022 press release [accessed 2022 Nov 10]. https:\/\/www.taisho.co.jp\/global\/news\/2022\/20220926001109.html."},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42273"},{"key":"e_1_3_5_70_1","unstructured":"Genor Biopharma Co. Inc. 1H 2022 Interim results presentation. August 2022 presentation [accessed 2022 Sept 19]. https:\/\/www.genorbio.com\/media\/1300\/1h22-interim-results-presentation.pdf."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5526"},{"key":"e_1_3_5_72_1","unstructured":"Sorrento Therapeutics Inc. Sorrento\u2019s license partner Lee\u2019s Pharm announces full enrollment of 498 patients in a Phase III trial of socazolimab (anti-PD-L1 antibody) for first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). May 17 2022 press release [accessed 2022 Sept 19]. https:\/\/investors.sorrentotherapeutics.com\/news-releases\/news-release-details\/sorrentos-license-partner-lees-pharm-announces-full-enrollment."},{"key":"e_1_3_5_73_1","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Ltd. Pipeline highlights as of September 2022. [accessed 2022 Nov 19]. www.hengrui.com\/en\/pipeline.html."},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"e_1_3_5_75_1","unstructured":"Pharma K. Pipeline. [accessed 2022 Nov 19]. www.kluspharma.com\/pipeline."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209509"},{"key":"e_1_3_5_77_1","unstructured":"Chugai Pharmaceutical Co. Ltd. Anti-C5 recycling antibody crovalimab obtains priority review in China for the treatment of paroxysmal nocturnal hemoglobinuria. August 10 2022 press release [accessed 2022 Aug 30]. www.chugai-pharm.co.jp\/english\/news\/detail\/20220810160000_942.html."},{"key":"e_1_3_5_78_1","unstructured":"CSPC Pharmaceutical Group Limited. Biologics license application for JMT103 accepted by the NMPA. June 22 2022 press release [accessed 2022 Aug 30]. https:\/\/doc.irasia.com\/listco\/hk\/cspc\/announcement\/a220622.pdf."},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971594"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.11526"},{"key":"e_1_3_5_81_1","unstructured":"Innovent Biologics Inc. Innovent announces the NMPA acceptance of the new drug application for tafolecimab injection (anti-PCSK-9 antibody). June 14 2022 press release [accessed 2022 Aug 30]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=332."},{"key":"e_1_3_5_82_1","unstructured":"Innovent Biologics Inc. Innovent announces two registration studies of IBI306 (anti-PCSK-9 antibody) met primary endpoint. February 17 2022 press release [accessed 2022 Aug 30]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=306."},{"key":"e_1_3_5_83_1","volume-title":"April","volume":"4","author":"Innovent Biologics, Inc","year":"2022","unstructured":"Innovent Biologics, Inc. Innovent releases results of a Phase 3 clinical study of IBI306 (PCSK-9 inhibitor) in Chinese patients with heterozygous familial hypercholesterolemia at the American College of Cardiology Annual Congress 2022. April 4, 2022 press release [accessed 2022 Sept 19]. https:\/\/www.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=314."},{"key":"e_1_3_5_84_1","unstructured":"Pharma Japan. Novo seeks Japan approval of hemophilia drug concizumab. August 31 2022 business news [accessed 2022 Nov 25]. https:\/\/pj.jiho.jp\/article\/247369."},{"key":"e_1_3_5_85_1","unstructured":"Jim\u00e9nez-Yuste V Angchaisuksiri P Castaman G Cepo K Haaning J Jacobsen S Mahlangu J Matsushita T Nogami K Shapiro A Concizumab prophylaxis in patients with haemophilia A or B with inhibitors: efficacy and safety results from the primary analysis of the Phase 3 explorer7 trial. Abstract Number: LB 01.2; International Society on Thrombosis and Haemostasis London UK; July 9-13 2022. [accessed 2022 July 9-13]. https:\/\/abstracts.isth.org\/abstract\/concizumab-prophylaxis-in-patients-with-haemophilia-a-or-b-with-inhibitors-efficacy-and-safety-results-from-the-primary-analysis-of-the-phase-3-explorer7-trial\/."},{"key":"e_1_3_5_86_1","unstructured":"Coherus BioSciences Inc. Shanghai Junshi Biosciences Co. Ltd. Coherus and Junshi Biosciences announce FDA acceptance of resubmission of BLA for toripalimab for the treatment of nasopharyngeal carcinoma. July 6 2022 press release [accessed 2022 Oct 15]. https:\/\/investors.coherus.com\/news-releases\/news-release-details\/coherus-and-junshi-biosciences-announce-fda-acceptance."},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01444-0"},{"key":"e_1_3_5_88_1","unstructured":"U.S. Food and Drug Administration. FDA approval of lymphoma medicine Ukoniq (umbralisib) is withdrawn due to safety concerns. June 1 2022 FDA Drug Safety Communication [accessed 2022 Oct 15]. https:\/\/www.fda.gov\/media\/158834\/download."},{"key":"e_1_3_5_89_1","unstructured":"TG Therapeutics Inc. TG Therapeutics announces FDA extension of BLA PDUFA date for ublituximab to treat patients with RMS. May 31 2022 press release [accessed 2022 Oct 15]. https:\/\/ir.tgtherapeutics.com\/news-releases\/news-release-details\/tg-therapeutics-announces-fda-extension-bla-pdufa-date."},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201904"},{"key":"e_1_3_5_91_1","unstructured":"Eisai Co. Ltd. Biogen Inc. The U.S. FDA accepts and grants priority review For Eisai\u2019s biologics license application of lecanemab for early Alzheimer\u2019s disease under the accelerated approval pathway. July 6 2022 press release [accessed 2022 Oct 15]. https:\/\/www.eisai.com\/news\/2022\/news202254.html."},{"key":"e_1_3_5_92_1","unstructured":"Eisai Co. Ltd. Biogen Inc. Lecanemab confirmatory Phase 3 clarity ad study met primary endpoint showing highly statistically significant reduction of clinical decline in large global clinical study of 1 795 participants with early Alzheimer\u2019s disease. September 27 2022 press release [accessed 2022 Oct 15]. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/lecanemab-confirmatory-phase-3-clarity-ad-study-met-primary."},{"key":"e_1_3_5_93_1","unstructured":"Byondis. Byondis and medac enter into license and collaboration and supply agreements for anti-HER2 ADC trastuzumab duocarmazine (SYD985). May 3 2022 press release [accessed 2022 Sept 19]. https:\/\/www.byondis.com\/media\/press-releases\/byondis-and-medac-enter-into-license-and-collaboration-and-supply-agreements-for-anti-her2-adc-trastuzumab-duocarmazine."},{"key":"e_1_3_5_94_1","unstructured":"Byondis. FDA accepts Byondis\u2019 biologics license application for [vic-]trastuzumab duocarmazine (SYD985) in HER2-positive metastatic breast cancer. July 12 2022 press release [accessed 2022 Sept 19]. https:\/\/www.byondis.com\/media\/press-releases\/fda-accepts-byondis-biologics-license-application-for-vic-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer."},{"key":"e_1_3_5_95_1","unstructured":"Byondis. EMA validates marketing authorization application for trastuzumab duocarmazine (SYD985) in HER2-positive metastatic breast cancer. July 18 2022 press release [accessed 2022 Sept 19]. https:\/\/www.byondis.com\/media\/press-releases\/ema-validates-marketing-authorization-application-for-trastuzumab-duocarmazine-syd985-in-her2-positive-metastatic-breast-cancer."},{"key":"e_1_3_5_96_1","unstructured":"Eli Lilly and Company. Nearly two-thirds of patients respond to mirikizumab treatment at 12 weeks in Lilly\u2019s first-in-class ulcerative colitis Phase 3 LUCENT-1 study. February 18 2022 press release [accessed 2022 Sep 25]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/nearly-two-thirds-patients-respond-mirikizumab-treatment-12."},{"key":"e_1_3_5_97_1","unstructured":"Eli Lilly and Company. Fifty percent of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in Lilly\u2019s pivotal Phase 3 study. May 24 2022 press release [accessed 2022 Sep 25]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fifty-percent-patients-ulcerative-colitis-treated-mirikizumab."},{"key":"e_1_3_5_98_1","unstructured":"Genentech. New pivotal data demonstrate clinical benefit of Genentech\u2019s glofitamab a potential first-in-class bispecific antibody for people with aggressive lymphoma. May 26 2022 press release [accessed 2022 Sept 19]. https:\/\/www.gene.com\/media\/press-releases\/14954\/2022-05-26\/new-pivotal-data-demonstrate-clinical-be."},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924542"},{"key":"e_1_3_5_100_1","unstructured":"Eli Lilly and Company. Lilly reports second-quarter financial results highlights momentum of new medicines and pipeline advancements. August 4 2022 press release [accessed 2022 Oct 15]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-reports-second-quarter-financial-results-highlights."},{"key":"e_1_3_5_101_1","unstructured":"Eli Lilly and Company. Lilly\u2019s donanemab slows clinical decline of Alzheimer\u2019s disease in positive Phase 2 trial. January 11 2021 press release [accessed 2022 Oct 15]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-donanemab-slows-clinical-decline-alzheimers-disease."},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793"},{"key":"e_1_3_5_103_1","unstructured":"Almirall SA Almirall announces EMA acceptance for filing of Marketing Authorization Application (MAA) for lebrikizumab in atopic dermatitis. October 28 2022 press release [accessed 2022 Nov 25]. https:\/\/www.almirall.com\/newsroom\/news\/almirall-announces-ema-acceptance-for-filing-of-marketing-authorization-application-maa-for-lebrikizumab-in-atopic-dermatitis."},{"key":"e_1_3_5_104_1","unstructured":"Almirall SA. Almirall: eight out of ten patients maintained skin clearance at one year in lebrikizumab atopic dermatitis monotherapy trials. June 7 2022 press release [accessed 2022 Sep 25]. https:\/\/www.almirall.com\/newsroom\/news\/almirall-eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lebrikizumab-atopic-dermatitis-monotherapy-trials-1."},{"key":"e_1_3_5_105_1","unstructured":"Genmab Inc. Genmab announces U.S. Food and Drug Administration accepts for priority review biologics license application (BLA) for Epcoritamab (DuoBody\u00ae-CD3xCD20) for the treatment of relapsed\/refractory large B-cell lymphoma (LBCL). 2022 Nov 21 press release [accessed 2022 Nov 21]. https:\/\/ir.genmab.com\/news-releases\/news-release-details\/genmab-announces-us-food-and-drug-administration-accepts."},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00889-8"},{"key":"e_1_3_5_107_1","volume-title":"at the European Hematology Association (EHA) Annual Congress","author":"AbbVie, Inc","unstructured":"AbbVie, Inc. AbbVie announces late-breaking results from Phase 2 trial of investigational epcoritamab (DuoBody\u00ae-CD3xCD20) in patients with relapsed\/refractory large B-cell lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress. June 11, 2022 Press Release [accessed 2022 Sep 25]. https:\/\/news.abbvie.com\/news\/press-releases\/abbvie-announces-late-breaking-results-from-phase-2-trial-investigational-epcoritamab-duobody-cd3xcd20-in-patients-with-relapsedrefractory-large-b-cell-lymphoma-lbcl-at-european-hematology-association-eha-annual-congress.htm."},{"key":"e_1_3_5_108_1","unstructured":"BeiGene LTD BeiGene announces acceptance of 11th regulatory submission for PD-1 inhibitor tislelizumab in China. August 23 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.beigene.com\/news\/beigene-announces-acceptance-of-11th-regulatory-submission-for-pd-1-inhibitor-tislelizumab-in-china\/2c7d63b6-7abe-441b-b23d-8d850c8f7ba4\/."},{"key":"e_1_3_5_109_1","unstructured":"BeiGene LTD BeiGene provides regulatory update on the U.S. biologics license application (BLA) for PD-1 inhibitor tislelizumab in 2L ESCC. July 14 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.beigene.com\/news\/beigene-provides-regulatory-update-on-the-u-s-biologics-license-application-bla-for-pd-1-inhibitor-tislelizumab\/09127f95-fd94-4a1b-b215-3e356e5fcfd9\/."},{"key":"e_1_3_5_110_1","unstructured":"Novartis. Novartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancers. April 6 2022 press release [accessed 2022 Sep 25]. https:\/\/www.novartis.com\/news\/media-releases\/novartis-announces-anti-pd-1-tislelizumab-accepted-ema-regulatory-review-esophageal-and-lung-cancers."},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01926"},{"key":"e_1_3_5_112_1","unstructured":"BeiGene LTD Results from RATIONALE 303: a global Phase 3 study of tislelizumab vs docetaxel as second- or third-line therapy for patients with locally advanced or metastatic NSCLC. BeiGene presentation [accessed 2022 Oct 5]. https:\/\/www.beigenemedical.com\/CongressDocuments\/Zhou_BGB-A317-303_AACR_presentation_2021.pdf."},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.005"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0366"},{"key":"e_1_3_5_115_1","unstructured":"U.S. Food and Drug Administration. Oncologic Drugs Advisory Committee Meeting June 24 2021: BLA 761209 \u2013 retifanlimab. [accessed 2022 Sep 25]. https:\/\/www.fda.gov\/media\/150325\/download."},{"key":"e_1_3_5_116_1","unstructured":"Incyte Corporation. Incyte provides regulatory update on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal (SCAC). July 23 2021 press release [accessed 2022 Sep 25]. https:\/\/investor.incyte.com\/news-releases\/news-release-details\/incyte-provides-regulatory-update-retifanlimab-treatment-certain."},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.935383"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02389"},{"key":"e_1_3_5_119_1","unstructured":"Omeros Corporation. Omeros Corporation receives decision from FDA on formal dispute resolution request for narsoplimab. November 8 2022 press release [accessed 2022 Nov 10]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-receives-decision-fda-formal-dispute."},{"key":"e_1_3_5_120_1","unstructured":"Innovent Biologics Inc. Eli Lilly and Company. BLA761222 ODAC - Sintilimab BLA in non-squamous NSCLC. February 10 2022 presentation [accessed 2022 Oct 15]. https:\/\/www.fda.gov\/media\/156090\/download."},{"key":"e_1_3_5_121_1","unstructured":"Eli Lilly and Company. Lilly announces complete response letter for sintilimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer. March 24 2022 press release [2022 Sep 25]. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-announces-complete-response-letter-sintilimab-combination."},{"key":"e_1_3_5_122_1","unstructured":"Y-mAbs Therapeutics Inc. Y-mAbs announces pivotal data for omburtamab. October 3 2022 press release [accessed 2022 Oct 15]. https:\/\/ir.ymabs.com\/news-releases\/news-release-details\/y-mabs-announces-pivotal-data-omburtamab."},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2123299"},{"key":"e_1_3_5_124_1","unstructured":"PhaseBio Pharmaceuticals Inc. PhaseBio Pharmaceuticals reports second quarter 2022 financial results and recent business highlights. August 12 2022 press release [accessed 2022 Sep 25]. https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-pharmaceuticals-reports-second-quarter-2022-financial."},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100047"},{"key":"e_1_3_5_126_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron corporate presentation. August 2022 [accessed 2022 Sep 25]. https:\/\/investor.regeneron.com\/static-files\/2bed4561-b43f-4fe6-be95-021f223cd7cb."},{"key":"e_1_3_5_127_1","unstructured":"CSL Limited. CSL announces positive top-line Phase 3 results for garadacimab as preventive treatment in patients with hereditary angioedema (HAE). August 17 2022 press release [accessed 2022 Sep 25]. https:\/\/www.csl.com\/news\/2022\/20220817-csl-announces-positive-results-for-garadacimab."},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13180"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100820"},{"key":"e_1_3_5_130_1","unstructured":"SinoMab BioScience Limited. Interim report 2022. [accessed 2022 Oct 15]. https:\/\/files.services\/files\/517\/2022\/0927\/20220927164502_35278113_en.pdf"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab699"},{"key":"e_1_3_5_132_1","unstructured":"Kodiak Sciences Inc. Kodiak Sciences announces second quarter 2022 financial results and recent business highlights. August 9 2022 press release [accessed 2022 Nov 10]. https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-announces-second-quarter-2022-financial-results."},{"key":"e_1_3_5_133_1","unstructured":"Kodiak Sciences Inc. Corporate presentation August 2022. [accessed 2022 Nov 19]. https:\/\/ir.kodiak.com\/static-files\/687f81e2-520a-4b6e-a91b-cc06da614bb4."},{"key":"e_1_3_5_134_1","unstructured":"Kodiak Sciences Inc. KSI-301 anti-VEGF antibody biopolymer conjugate for retinal vein occlusion: primary 24-week efficacy and safety outcomes of the beacon phase 3 pivotal study September 30 2022 presentation. [accessed 2022 Sep 25]. https:\/\/ir.kodiak.com\/static-files\/f3a30a82-ed03-4313-acb1-73f22e2a0c4b."},{"key":"e_1_3_5_135_1","doi-asserted-by":"crossref","unstructured":"Syndax Pharmaceuticals Inc. Syndax Pharmaceuticals reports third quarter 2022 financial results and provides clinical and business update. November 3 2022 pess release [accessed 2022 Nov 10]. https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndax-pharmaceuticals-reports-third-quarter-2022-financial.","DOI":"10.1016\/j.fopow.2022.04.012"},{"key":"e_1_3_5_136_1","unstructured":"Innovent Biologics Inc. Innovent 2022 interim results August 2022. [accessed 2022 Oct 31]. https:\/\/img.innoventbio.com\/file1.pdf."},{"key":"e_1_3_5_137_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron corporate presentation August 2022. [accessed 2022 Oct 15]. https:\/\/investor.regeneron.com\/static-files\/2bed4561-b43f-4fe6-be95-021f223cd7cb."},{"key":"e_1_3_5_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_3_5_139_1","unstructured":"Checkpoint Therapeutics Inc. Checkpoint Therapeutics corporate presentation September 2022. [accessed 2022 Sep 25]. https:\/\/ir.checkpointtx.com\/company-information\/presentations."},{"key":"e_1_3_5_140_1","unstructured":"Checkpoint Therapeutics Inc. Checkpoint Therapeutics reports second quarter 2022 financial results and recent corporate highlights. August 12 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.checkpointtx.com\/news-events\/press-releases\/detail\/87\/checkpoint-therapeutics-reports-second-quarter-2022."},{"key":"e_1_3_5_141_1","unstructured":"Actinium Pharmaceuticals Inc. Actinium Investor Presentation September 2022. [accessed 2022 Sep 25]. https:\/\/d1io3yog0oux5.cloudfront.net\/_f3b741a645f0b39c25728ef872153297\/actiniumpharma\/db\/206\/944\/pdf\/Actinium_Investor+Presentation_September+2022.pdf"},{"key":"e_1_3_5_142_1","unstructured":"Actinium Pharmaceuticals Inc. Actinium announces positive top-line results from pivotal Phase 3 SIERRA trial of Iomab-B in patients with active relapsed or refractory acute myeloid leukemia. October 31 2022 press release [accessed 2022 Oct 31]. https:\/\/ir.actiniumpharma.com\/press-releases\/detail\/428\/actinium-announces-positive-top-line-results-from-pivotal."},{"key":"e_1_3_5_143_1","volume-title":"the Phase 3 SIERRA trial successfully engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR","author":"Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc","unstructured":"Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. announces 82% of control arm patients did not receive a bone marrow transplant by conventional means but 100% of patients who received Iomab-B, including crossover patients, in the Phase 3 SIERRA trial successfully engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR. April 25, 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.actiniumpharma.com\/press-releases\/detail\/421\/actinium-pharmaceuticals-inc-announces-82-of-control-arm."},{"key":"e_1_3_5_144_1","unstructured":"AstraZeneca. Clinical trials appendix H1 2022 results update [accessed 2022 Sep 25]. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2022\/h1-2022\/H1-2022-results-clinical-trials-appendix.pdf."},{"key":"e_1_3_5_145_1","unstructured":"Astellas Pharma Inc. Integrated report 2022 for the year ending March 31 2022. [accessed 2022 October 5]. https:\/\/www.astellas.com\/en\/system\/files\/astellas_ir2022_en_20221004.pdf."},{"key":"e_1_3_5_146_1","unstructured":"Astellas Pharma Inc. Astellas announces zolbetuximab meets primary endpoint in Phase 3 SPOTLIGHT trial as first-line treatment in Claudin 18.2 positive HER2-negative locally advanced or metastatic gastric and gastroesophageal junction (GEJ) cancers. November 17 2022 press release [accessed 2022 Nov 17]. https:\/\/www.astellas.com\/en\/news\/26821."},{"key":"e_1_3_5_147_1","unstructured":"Elevar Therapeutics Inc. Elevar Therapeutics announces positive pre-NDA meeting for rivoceranib combination with camrelizumab as hepatocellular carcinoma treatment option. October 11 2022 press release [accessed 2022 Oct 31]. https:\/\/elevartherapeutics.com\/2022\/10\/11\/elevar-therapeutics-announces-positive-pre-nda-meeting-for-rivoceranib-combination-with-camrelizumab-as-hepatocellular-carcinoma-treatment-option\/."},{"key":"e_1_3_5_148_1","unstructured":"Jiangsu Hengrui Pharmaceuticals Co. Ltd. Camrelizumab in combination with rivoceranib (apatinib) significantly prolonged overall survival and progression-free survival vs sorafenib in patients with unresectable hepatocellular carcinoma in a multinational Phase 3 trial a joint program with Elevar Therapeutics. September 10 2022 press release [2022 Oct 31]. https:\/\/www.hengrui.com\/en\/media\/detail-254.html."},{"key":"e_1_3_5_149_1","unstructured":"CStone Pharmaceuticals. CStone Pharmaceuticals reports 2022 interim results and business updates. August 25 2022 press release [accessed 2022 Oct 31]. https:\/\/www.cstonepharma.com\/en\/html\/news\/2808.html."},{"key":"e_1_3_5_150_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7501"},{"key":"e_1_3_5_151_1","unstructured":"I-Mab Biopharma. I-Mab partner MorphoSys announces new license agreements for felzartamab and TJ210. June 15 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.i-mabbiopharma.com\/news-releases\/news-release-details\/i-mab-partner-morphosys-announces-new-license-agreements."},{"key":"e_1_3_5_152_1","unstructured":"I-Mab Biopharma. Pioneering the Next-Generation of Immuno-Oncology. October 2022 corporate presentation [accessed 2022 Nov 25]. https:\/\/ir.i-mabbiopharma.com\/system\/files-encrypted\/nasdaq_kms\/assets\/2022\/10\/19\/7-56-59\/Corporate%20Presentation_Oct%202022_v2.pdf."},{"key":"e_1_3_5_153_1","unstructured":"Sanofi. Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China. August 4 2022 press release [accessed 2022 Sep 25]. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-08-04-15-30-00-2492626."},{"key":"e_1_3_5_154_1","unstructured":"Sanofi. Sanofi Q2 2022 results. July 28 2022 presentation. [accessed 2022 Sep 25]. www.sanofi.com\/dam\/jcr:2c6b06a7-37bd-4a6a-b243-3ac5cee2752c\/2022_07_28_Sanofi_Q2_2022_Results.pdf"},{"key":"e_1_3_5_155_1","unstructured":"Roche Group. Roche YTD September 2022 sales. October 18 2022 presentation with appendix [accessed 2022 Nov 10]. https:\/\/www.roche.com\/investors\/events\/q3-2022."},{"key":"e_1_3_5_156_1","unstructured":"Roche Group. Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. May 11 2022 Roche press release [accessed 26 Sep 2022]. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-05-11."},{"key":"e_1_3_5_157_1","unstructured":"Pfizer Inc. Pfizer\u2019s elranatamab granted FDA Breakthrough Therapy designation for relapsed or refractory multiple myeloma. November 3 2022 press release [accessed 2022 Nov 10]. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizers-elranatamab-granted-fda-breakthrough-therapy."},{"key":"e_1_3_5_158_1","unstructured":"Pfizer Inc. Second quarter 2022 earnings teleconference. July 28 2022 [accessed 2022 Sep 25]. https:\/\/s28.q4cdn.com\/781576035\/files\/doc_financials\/2022\/q2\/Q2-2022-Earnings-Charts-FINAL.pdf."},{"key":"e_1_3_5_159_1","unstructured":"CStone Pharmaceuticals. Investor presentation July 2022. [accessed 2022 Sep 25]. https:\/\/www.cstonepharma.com\/en\/uploads\/2022\/07\/165846866935356.pdf."},{"key":"e_1_3_5_160_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16191"},{"key":"e_1_3_5_161_1","unstructured":"Alphamab Oncology. The first interim analysis of KN046 Phase III trial successfully reached prespecified PFS endpoint. March 31 2022 press release [accessed 2022 Sep 25]. https:\/\/www.alphamabonc.com\/en\/html\/news\/2414.html."},{"key":"e_1_3_5_162_1","volume-title":"European Society for Medical Oncology Congress","author":"Zhao Y","unstructured":"Zhao Y, Chen G, Li X, Wu J, Chang B, Hu S, Yang S, Liu Y, Wang N, Huang Y, et al. Two-year follow-up from KN046 in combination with platinum doublet chemotherapy as first-line (1L) treatment for NSCLC: an open-label, multi-center phase II trial. European Society for Medical Oncology Congress, September 10, 2022, Paris, France. Poster session 14; abstract 1029P. [accessed 2022 Sep 25]. https:\/\/oncologypro.esmo.org\/meeting-resources\/esmo-congress\/two-year-follow-up-from-kn046-in-combination-with-platinum-doublet-chemotherapy-as-first-line-1l-treatment-for-nsclc-an-open-label-multi-center."},{"key":"e_1_3_5_163_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron corporate presentation August 2022. [accessed 2022 Sep 25]. https:\/\/investor.regeneron.com\/static-files\/2bed4561-b43f-4fe6-be95-021f223cd7cb."},{"key":"e_1_3_5_164_1","unstructured":"Regeneron Pharmaceuticals Inc. New REGN5458 (BCMAXCD3) Phase 1 data show 75% response rate at highest dose levels studied in patients with heavily pretreated multiple myeloma. December 11 2021 press release [accessed 2022 Sep 25]. https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/new-regn5458-bcmaxcd3-phase-1-data-show-75-response-rate-highest."},{"key":"e_1_3_5_165_1","unstructured":"Jazz Pharmaceuticals plc. Jazz Pharmaceuticals and Zymeworks announce exclusive license agreement to develop and commercialize zanidatamab a HER2-targeted bispecific antibody. October 19 2022 press release [accessed 2022 Oct 31]. http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-and-zymeworks-announce-exclusive-license."},{"key":"e_1_3_5_166_1","unstructured":"Zymeworks Inc. Zymeworks reports last patient enrolled in pivotal study of zanidatamab in treatment of HER2-expressing late-line biliary tract cancer. April 28 2022 press release [accessed 2022 Sep 25]. https:\/\/ir.zymeworks.com\/news-releases\/news-release-details\/zymeworks-reports-last-patient-enrolled-pivotal-study."},{"key":"e_1_3_5_167_1","unstructured":"Zymeworks Inc. Corporate presentation September 2022. [accessed 2022 Oct 31]. https:\/\/ir.zymeworks.com\/static-files\/efbb3a4f-99d3-4eb2-9c9f-681abd2e1b6c."},{"key":"e_1_3_5_168_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0595"},{"key":"e_1_3_5_169_1","unstructured":"The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen announces U.S. FDA Breakthrough Therapy designation granted for talquetamab for the treatment of relapsed or refractory multiple myeloma. June 29 2022 press release [accessed 2022 Nov 17]. https:\/\/www.janssen.com\/us\/sites\/www_janssen_com_usa\/files\/janssen_announces_us_fda_breakthrough_therapy_designation_granted_for_talquetamab_for_the_treatment_of_relapsed_or_refractory_multiple_myeloma.pdf."},{"key":"e_1_3_5_170_1","doi-asserted-by":"crossref","unstructured":"Minnema MC Krishnan A Berdeja JG Oriol A van de Donk NWCJ Rodr\u00edguez-Otero P Morillo D Mateos M-V Costa LJ Caers J et al. Talquetamab a G protein-coupled receptor family C Group 5 member D x CD3 bispecific antibody in relapsed\/refractory multiple myeloma: updated efficacy and safety results from MONUMENTAL-1. Abstract release date: 05\/26\/22 EHA Library [accessed 2022 Nov 17]. https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/357046\/monique.c.minnema.talquetamab.a.g.protein-coupled.receptor.family.c.group.5.html.","DOI":"10.1097\/01.HS9.0000843620.09412.35"},{"key":"e_1_3_5_171_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron reports third quarter 2022 financial and operating results. November 3 2022 press release [accessed 2022 Nov 17]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-reports-third-quarter-2022-financial-and-operating."},{"key":"e_1_3_5_172_1","unstructured":"Nordic Nanovector ASA and APIM Therapeutics. Nordic Nanovector and APIM Therapeutics announce merger agreement. November 9 2022 press release [accessed 2022 Nov 19]. https:\/\/www.prnewswire.com\/news-releases\/nordic-nanovector-and-apim-therapeutics-announce-merger-agreement-301673852.html."},{"key":"e_1_3_5_173_1","unstructured":"Ambrx Biopharma Inc. Ambrx Biopharma Inc. announces strategic reprioritization and provides corporate update. October 18 2022 press release [accessed 2022 Nov 17]. https:\/\/ir.ambrx.com\/news\/news-details\/2022\/Ambrx-Biopharma-Inc.-Announces-Strategic-Reprioritization-and-Provides-Corporate-Update\/default.aspx."},{"key":"e_1_3_5_174_1","unstructured":"Roche. Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer\u2019s disease. November 14 2022 press release [accessed 2022 Nov 19]. https:\/\/www.roche.com\/media\/releases\/med-cor-2022-11-14"},{"key":"e_1_3_5_175_1","unstructured":"Sesen Bio Inc. Carisma Therapeutics Inc. Sesen Bio and Carisma Therapeutics announce merger agreement. September 21 2022 press release [accessed 2022 Nov 19]. https:\/\/carismatx.com\/sesen-bio-and-carisma-therapeutics-announce-merger-agreement\/"},{"key":"e_1_3_5_176_1","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C Ansell S Zinzani PL Radford J Maddocks K Pinto A Collins GP Bachanova V Bartlett N Bence-Bruckler I et al. Camidanlumab tesirine: updated efficacy and safety in an open-label multicenter Phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (r\/r CHL). European Hematology Association Hybrid Congress June 10 2022 Vienna (Austria). https:\/\/library.ehaweb.org\/eha\/2022\/eha2022-congress\/357065\/carmelo.carlo-stella.camidanlumab.tesirine.updated.efficacy.and.safety.in.an.html.","DOI":"10.1097\/01.HS9.0000843696.37630.1c"},{"key":"e_1_3_5_177_1","unstructured":"ADC Therapeutics SA. ADC Therapeutics reports third quarter 2022 financial results and provides business updates. November 8 2022 press release [accessed 2022 Nov 19]. https:\/\/ir.adctherapeutics.com\/press-releases\/press-release-details\/2022\/ADC-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Business-Updates\/default.aspx."},{"key":"e_1_3_5_178_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2208954"},{"key":"e_1_3_5_179_1","unstructured":"GSK. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorization. November 22 2022 press release [accessed 2022 Nov 22]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-provides-update-on-blenrep-us-marketing-authorisation\/"}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2022.2153410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:13:43Z","timestamp":1753258423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2022.2153410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":178,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/19420862.2022.2153410"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2022.2153410","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2153410"}}